論文

国際誌
2021年1月1日

Local administration of high-dose diabetes medicine exendin-4 inhibits orthodontic tooth movement in mice.

The Angle orthodontist
  • Wei-Ren Shen
  • ,
  • Hideki Kitaura
  • ,
  • Jiawei Qi
  • ,
  • Saika Ogawa
  • ,
  • Fumitoshi Ohori
  • ,
  • Takahiro Noguchi
  • ,
  • Aseel Marahleh
  • ,
  • Yasuhiko Nara
  • ,
  • Pramusita Adya
  • ,
  • Itaru Mizoguchi

91
1
開始ページ
111
終了ページ
118
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2319/021320-103.1

OBJECTIVES: To investigate the effects of exendin-4 on orthodontic tooth movement distance, root resorption, and expression levels of osteoclast-related cytokines in a mouse model. MATERIALS AND METHODS: A 10-g NiTi coil spring was placed between the anterior alveolar bone and upper left first molar of 8-week-old male C57BL/6 mice. Twenty microliters of exendin-4 solution (containing 0.2 μg, 4 μg, or 20 μg exendin-4) or phosphate-buffered saline (PBS) were injected on the buccal side of the upper left first molar at 2-day intervals (4 mice per group). Mice were sacrificed on day 12; silicone impressions were taken to record tooth movement distance. The left maxillae of the PBS and 20 μg exendin-4 groups were also excised for histological analysis and quantitative reverse transcription polymerase chain reaction analysis. RESULTS: Orthodontic tooth movement distance was smaller in the 20 μg exendin-4 group than in the PBS group (P < .01). Compared with the PBS group, the 20 μg exendin-4 group showed lower osteoclast number (P < .05), odontoclast number (P < .05), and root resorption surface percentage (P < .05). Relative to maxillae with PBS injections, maxillae with 20 μg exendin-4 injections had lower receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA expression (P < .05), TNF-α mRNA expression (P < .05), and RANKL/osteoprotegerin (OPG) ratio (P < .01). There were no differences in the expression of OPG mRNA. CONCLUSIONS: Exendin-4 inhibits orthodontic tooth movement. Therefore, additional attention is needed for orthodontic patients who receive exendin-4 for diabetes treatment. GLP-1 receptor may be a treatment target for patients with severe root resorption.

リンク情報
DOI
https://doi.org/10.2319/021320-103.1
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33289799
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032283
ID情報
  • DOI : 10.2319/021320-103.1
  • PubMed ID : 33289799
  • PubMed Central 記事ID : PMC8032283

エクスポート
BibTeX RIS